It is uncertain whether reactive thrombocytosis is associated with an increased risk of thrombosis. This prospective case-control study assessed the in vitro thrombotic tendency of patients with reactive thrombocytosis. Forty-eight patients with reactive thrombocytosis, defined by platelet count >500×10 9 /l and 55 similar, randomly selected critically ill patients who did not have reactive thrombocytosis were considered. In vitro thrombotic tendency in both groups of patients was assessed using the maximal amplitude (normal range 54 to 72 mm) and alpha angle (normal range 47 to 74°) on the thromboelastograph. The associations between reactive thrombocytosis and C-reactive protein, the coagulation profile and Sequential Organ Failure Assessment score were also evaluated. Patients with reactive thrombocytosis had an associated increased in vitro thrombotic tendency (maximal amplitude 77 vs 69 mm, mean difference 8 mm, 95% confidence interval 4.9 to 10.9, P=0.001), a higher fibrinogen concentration (7.2 vs 5.8 g/l, P=0.003), and a higher incidence of infection requiring antibiotics (50 vs 27%, P=0.025) compared to patients without thrombocytosis. Platelet count had a relatively linear relationship with the maximal amplitude and the alpha angle of the thrombo-elastograph tracing (Pearson correlation coefficient: 0.53, P=0.001).
Reactive thrombocytosis refers to thrombocytosis in the absence of a chronic myeloproliferative or myelodysplastic disorder and is associated with a number of medical conditions (Table 1) 1 . Reactive thrombocytosis can either be transient or sustained and is driven by elevated endogenous concentrations of thrombopoietin, interleukin-6 and other cytokines and catecholamines in situations of stress, inflammation or infection 2 .
It is well established that essential thrombocytosis in myeloproliferative diseases is associated with an increased risk of thrombosis due to the presence of giant platelets 1 . Whether reactive thrombosis due to an inflammatory or infective cause is associated with an increased risk of thrombosis remains controversial and uncertain. In reactive thrombocytosis the size and function of platelets are normal in nature and, as such, their interactions with the vessel wall should remain qualitatively normal, making thrombotic and bleeding complications less likely than in patients with essential thrombocythaemia 1, 3 . Some observational studies have, however, reported that reactive thrombocytosis is associated with an increased risk of thromboembolism, especially in patients with multiple trauma 4, 5 . Whether the association between thrombosis and reactive thrombocytosis in these studies was, in part, explained by confounding from the association between reactive thrombocytosis and severity of injury remains uncertain 6 .
Evidence of an increased in vitro thrombotic tendency in patients with reactive thrombocytosis is of paramount importance in proving the cause and effect relationship between reactive thrombocytosis and thromboembolism. We hypothesised that patients with reactive thrombocytosis would have evidence of an increased in vitro thrombotic tendency compared to patients who did not have reactive thrombocytosis, and conducted a prospective case-control study to assess the relationship between platelet counts and the magnitude of in vitro thrombotic tendency.
MATERIALS AND METHOD Setting and participants
This was a prospective case-control study. After obtaining Royal Perth Hospital Ethics Committee approval (EC2009/098), a total of 48 patients with reactive thrombocytosis, defined by platelet count >500×10 9 /l, and 55 randomly selected patients who did not have thrombocytosis in the intensive care unit (ICU) were recruited. Patients who were younger than 18 years old, pregnant or expected to die within 72 hours were excluded from the study. Those who had haematological malignancies or were receiving treatment with any anti-platelet agents were also excluded. Because of the observational nature of the study and the small volume of blood (~1 to 2 ml) needed, enrolment into the study required only acknowledgement by the next of kin of the patients if the patients were deemed to be incompetent to give informed written consent.
Data collection
Evidence suggests that the thromboelastograph (TEG) is a more reliable indicator of a hypercoagulable state than commonly used coagulation tests 7, 8 . In this study, in vitro thrombotic tendency was assessed using the maximal amplitude (MA) on the TEG (TEG 5000 Thromboelastograph ® Haemostasis Analyzer, Medtel, Lane Cove, NSW, normal range 54 to 72 mm). According to the recommendation of the manufacturer of the TEG machine, a MA >74 mm is regarded as an increased in vitro thrombotic tendency. In this study we defined evidence of a strong in vitro thrombotic tendency by a MA >80 mm, which also corresponded to the upper limit of the interquartile range of the MA values of all study patients. The angle on the TEG tracing (normal range 47 to 74°) was related to MA and was also used as a secondary marker of increased in vitro thrombotic tendency in the study.
Two channels of TEG, one using kaolin as activating agent and the other using kaolin with heparinase, were conducted for all study patients. The Medtel Thromboelastograph provides a comprehensive in vitro evaluation of the overall coagulation function of the whole blood sample.
All whole blood samples were tested within four minutes of sampling at the patient's body temperature. Because most study patients were receiving unfractionated heparin subcutaneously for thromboprophylaxis, TEG data on the MA and angle of the TEG tracing from the heparinase channel was used for all patients for consistency purposes.
The other data collected included demographic factors, diagnosis, Acute Physiology and Chronic Health Evaluation II score, Sequential Organ Failure Assessment score on the day of TEG testing 9 , C-reactive protein concentration 10 , fibrinogen concentration, International Normalised Ratio, activated partial thromboplastin time, active infection requiring antibiotics, thrombotic complications (deep vein thrombosis, pulmonary embolism, thrombotic stroke) and hospital mortality.
Statistical analysis
Categorical variables and continuous variables with skewed distributions were compared by chisquare and Mann-Whitney tests respectively. The quantitative relationships between platelet counts and MA or angle on the TEG and between platelet counts and inflammatory markers, such as C-reactive protein and fibrinogen, were analysed by scatter plots, and the Pearson correlation coefficient was used to assess the degree of linear relationships between these variables. The relationship between reactive thrombocytosis and evidence of having a strong in vitro thrombotic tendency (MA >80 mm) was analysed by multivariable logistic regression after adjusting for clinical and laboratory variables that were associated with a P value <0.25 in the univariable analyses.
Because of the small sample size of the study, a parsimony model, obtained by eliminating variables associated with a P value of >0.05 in a step-bystep fashion, was presented in addition to the full multivariable model. A P value <0.05 was taken as significant and all analyses were two-tailed and conducted by SPSS for Windows (version 19.0, 2011, IL USA) in this study.
RESULTS
A total of 54 patients with reactive thrombocytosis were recruited during the study period between July 2010 and June 2011. Six patients were subsequently found to have been treated with an anti-platelet agent, either aspirin or clopidogrel, within one week of enrolment and were excluded from the study. A total of 55 critically ill patients who had normal platelet counts during the study period were randomly selected as controls. None of these randomly selected patients were taking any anti-platelet agents before study enrolment.
The mean MA of the whole cohort was 73 mm (interquartile range 67 to 79) ( Figure 1 ). Patients with reactive thrombocytosis were significantly more likely to demonstrate evidence of an increased in vitro thrombotic tendency than were patients in the control group without evidence of reactive thrombocytosis (MA >74 mm: 77 vs 29%, P=0.001, and mean MA 77 vs 69 mm, mean difference 8 mm, Platelet count had a relatively linear relationship with the MA (Pearson correlation coefficient: 0.53, P=0.001) ( Figure 2 ) and angle of the TEG tracing (Pearson correlation coefficient 0.52, P=0.001) (Figure 3 ). There was also a significant, but weaker, association between platelet counts and fibrinogen (Pearson correlation coefficient 0.27, P=0.006) and platelet count and C-reactive protein concentration. (Pearson correlation coefficient 0.23, P=0.031) (Figures 4 and 5) .
In the multivariate analysis, only reactive thrombocytosis (odds ratio 5.9, 95% confidence interval 1.3 to 27.8, P=0.025) and activated partial thromboplastin time (odds ratio 0.93, 95% confidence interval 0.87 to 0.99, P=0.014) were significantly associated with evidence of having a strong in vitro thrombotic tendency in the full multivariable and parsimony models (Table 3) ; clinical diagnosis, fibrinogen concentration and Sequential Organ Failure Assessment score were not significantly associated with evidence of a strong in vitro thrombotic tendency.
DISCUSSION
Our results showed that reactive thrombocytosis was more common in critically ill patients with infection requiring antibiotics and that high platelet counts in reactive thrombocytosis were associated with evidence of an increased in vitro whole blood clotting tendency in a relatively linear fashion.
An elevated platelet count on routine laboratory blood testing has diagnostic, therapeutic and prognostic implications 11 . In the first instance, patients should be carefully evaluated to distinguish between essential and reactive thrombocytosis. Unlike essential thrombocytosis, which can cause both arterial and venous thrombosis 12 , reactive thrombocytosis has been traditionally considered as inconsequential without requiring anti-platelet therapy 1, 3 . Recent observational studies have however, suggested that reactive thrombocytosis is common in critically ill trauma patients (20%) and may not be innocuous 6 . Observational studies by Salim et al and Kashuk et al showed that reactive thrombocytosis was associated with a two-fold increase in the risk of thrombotic complications in patients with multiple trauma 4, 5 . The increased in vitro thrombotic tendency of our patients with reactive thrombocytosis was consistent with the results of these observational studies and requires careful consideration.
First, our results showed that an increased in vitro thrombotic tendency, as measured by the MA of the TEG tracing, was common in critically ill patients (54%). This result was consistent with results of many observational studies; the incidence and prevalence of venous thromboembolism in critically ill patients is indeed high and omission of early thromboprophylaxis is associated with an increased risk of mortality [13] [14] [15] [16] . Second, we established that reactive thrombocytosis was associated with evidence of an increased in vitro thrombotic tendency. The relatively linear relationship between platelet counts and the MA and angle of the TEG suggested that there might be a 'dose-related' effect between platelet count and in vitro thrombotic tendency in patients with reactive thrombocytosis. As such, our findings support a possible cause and effect association between reactive thrombocytosis and the clinical thromboses reported in recent observational studies 4, 5 .
The final consideration was the limitations of this study. In the first instance, the sample size of this study was small and was not powered to assess the relationship between risk of clinical thrombosis and reactive thrombocytosis. As such, the insignificant difference in incidence of venous thromboembolism between the two groups of patients included in this study was most likely due to inadequate statistical power. Second, many of our patients who had reactive thrombocytosis were discharged from the ICU when the platelet count was still high. Whether the increase in maximal amplitude on the TEG of the patients with reactive thrombocytosis will return to normal after platelet counts return to normal remains uncertain, but this deserves further investigation. Third, anti-platelet agents were not used for patients with reactive thrombocytosis by most attending clinicians of the patients in this study. Whether anti-platelet agents can reduce MA in patients with reactive thrombocytosis remains uncertain and warrants further investigation. Finally, although we have demonstrated a relatively linear relationship between platelet count and an in vitro thrombotic tendency, this may still be, in part, explained by confounding due to the interrelated associations between platelet count, inflammatory markers such as fibrinogen concentrations and an increase in MA of the TEG. In summary, the results of our study suggested that reactive thrombocytosis was more common in critically ill patients with infection requiring antibiotics, and that high platelet counts in reactive thrombocytosis were associated with evidence of an increased in vitro whole blood clotting tendency in a relatively linear fashion. More research is needed to confirm whether treating reactive thrombocytosis with anti-platelet agents can improve patient-centred outcomes.
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